Axiom Brain Health, in partnership with the Global Alzheimer’s Platform Foundation (GAP), launched its newly renovated research facility in Tampa, Florida. The expansion aims to address the growing need for research on neurodegenerative diseases like Alzheimer’s, Multiple Sclerosis, and Parkinson’s. The event highlighted the importance of volunteers, or “citizen scientists,” in advancing this research.
This expansion is crucial for the Tampa community and the broader fight against neurodegenerative diseases. The increased capacity allows Axiom to conduct more clinical trials, potentially accelerating the development of new therapies and diagnostic tools. With an estimated 580,000 individuals currently living with Alzheimer’s in Florida and projections for significant increases, the expanded facility positions Axiom to directly address this growing public health crisis. The emphasis on volunteer participation also underscores the vital role the community can play in advancing research.
The renovated facility has nearly tripled in size, from 1,700 to 3,900 square feet, and now houses 14 research experts, up from the original team of six. This expansion significantly increases the site’s capacity for conducting complex clinical trials and collecting valuable data. The growth not only benefits research efforts but also offers more opportunities for local residents to participate in cutting-edge studies.
This expansion represents a significant step forward in neurodegenerative disease research. The larger facility, increased staff, and emphasis on community involvement create a strong foundation for accelerating the development of much-needed treatments and improving the lives of those affected by these debilitating conditions. The continued collaboration between Axiom and GAP promises to further enhance research efforts and broaden access to clinical trials for the Tampa community.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
